Back to Search
Start Over
UCB: innovative payment scheme behind Cimzia approval sets precedent in rheumatology.
- Source :
- PharmaWatch: Biotechnology; Mar2010, Vol. 9 Issue 3, p9-9, 1p
- Publication Year :
- 2010
-
Abstract
- In this article the author discusses the approval of new rheumatoid arthritis drug Cimzia which is produced by UCB Inc.. The author notes that the National Health Service (NHS) has recommended Cimzia but only with a company-sponsored patient access scheme. The author mentions that UCB plans to pay for the first 12 weeks of a patient's therapy including the homecare provider to assist patients.
- Subjects :
- DRUG approval
RHEUMATOID arthritis treatment
PHARMACEUTICAL services
Subjects
Details
- Language :
- English
- Volume :
- 9
- Issue :
- 3
- Database :
- Complementary Index
- Journal :
- PharmaWatch: Biotechnology
- Publication Type :
- Report
- Accession number :
- 48594627